A novel therapeutic approach to 6-OHDA-induced Parkinson's disease in rats via supplementation of PTD-conjugated tyrosine hydroxylase

Biochemical and Biophysical Research Communications

Volumn 346, Issue 1, 2006, Pages 1-6

  Wu, Shao Ping ^a,b   Fu, Ai Ling ^a   Wang, Yu Xia ^a   Yu, Lei Ping ^c   Jia, Pei Yuan ^a   Li, Qian ^a   Jin, Guo Zhang ^c   Sun, Man Ji ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

6 Hydroxydopamine; Parkinson's disease; Protein transduction domain; Tyrosine hydroxylase

Indexed keywords

OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; EVALUATION; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR WEIGHT; NEUROBLASTOMA CELL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; APOMORPHINE; BLOOD-BRAIN BARRIER; BRAIN CHEMISTRY; CELL LINE, TUMOR; GENE PRODUCTS, TAT; HUMANS; MALE; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; ROTATION; STEREOTYPED BEHAVIOR; TRANSDUCTION, GENETIC; TYROSINE 3-MONOOXYGENASE;

ESCHERICHIA COLI;

EID: 33745009995     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.03.247     Document Type: Article

References (25)

1. Tanner C.M., and Goldman S.M. Epidemiology of Parkinson's disease. Neurol. Clin. 14 (1996) 317-335
2. Bushnell D.M., and Martin M.L. Quality of life and Parkinson's disease: translation and validation of the US Parkinson's Disease Questionnaire (PDQ-39). Qual. Life Res. 8 (1999) 345-350
3. Chase T.N., Oh J.D., and Blanchet P.J. Neostriatal mechanisms in Parkinson's disease. Neurology 51 (1998) S30-S35
4. Nagatsu T., Mogi M., Ichinose H., and Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural. Transm. Suppl. (2000) 277-290
5. Dunnett S.B., and Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399 (1999) A32-A39
6. Nagatsu T., Levitt M., and Udenfriend S. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J. Biol. Chem. 239 (1964) 2910-2917
7. Lu L., Zhao C., Liu Y., Sun X., Duan C., Ji M., Zhao H., Xu Q., and Yang H. Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease. Brain Res. Brain Res. Protoc. 15 (2005) 46-51
8. Pardridge W.M. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. NeuroRx. 2 (2005) 129-138
9. Cao L., Zhao Y.C., Jiang Z.H., Xu D.H., Liu Z.G., Chen S.D., Liu X.Y., and Zheng Z.C. Long-term phenotypic correction of rodent hemiparkinsonism by gene therapy using genetically modified myoblasts. Gene. Ther. 7 (2000) 445-449
10. A.R. Brenneman, S. Kaufman, The role of tetra-hydropteridines in the enzymatic conversion of tyrosine to 3,4-dihydroxyphenylalanine, Biochem. Biophys. Res. Commun. 17, 177-183.
11. Schwarze S.R., Hruska K.A., and Dowdy S.F. Protein transduction: unrestricted delivery into all cells?. Trends Cell Biol. 10 (2000) 290-295
12. Fu A.L., Huang S.J., and Sun M.J. Complementary remedy of aged-related learning and memory deficits via exogenous choline acetyltransferase. Biochem. Biophys. Res. Commun. 336 (2005) 268-273
13. Ryu J., Lee H.J., Kim K.A., Lee J.Y., Lee K.S., Park J., and Choi S.Y. Intracellular delivery of p53 fused to the basic domain of HIV-1 Tat. Mol. Cells 17 (2004) 353-359
14. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
15. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1998), Academic Press, San Diego
16. Tanaka T., Iqbal K., Trenkner E., Liu D.J., and Grundke-Iqbal I. Abnormally phosphorylated tau in SY5Y human neuroblastoma cells. FEBS Lett. 360 (1995) 5-9
17. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. Neurosci. Res. 2 (2005) 3-14
18. Leifert J.A., and Whitton J.L. "Translocatory proteins" and "protein transduction domains": a critical analysis of their biological effects and the underlying mechanisms. Mol. Ther. 8 (2003) 13-20
19. Fu A.L., Li Q., Dong Z.H., Huang S.J., Wang Y.X., and Sun M.J. Alternative therapy of Alzheimer's disease via supplementation with choline acetyltransferase. Neurosci. Lett. 368 (2004) 258-262
20. Kilic U., Kilic E., Dietz G.P., and Bahr M. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke 34 (2003) 1304-1310
21. Vives E., Brodin P., and Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272 (1997) 16010-16017
22. Yang Y., Ma J., Song Z., and Wu M. HIV-1 TAT-mediated protein transduction and subcellular localization using novel expression vectors. FEBS Lett. 532 (2002) 36-44
23. Trehin R., Krauss U., Muff R., Meinecke M., Beck-Sickinger A.G., and Merkle H.P. Cellular internalization of human calcitonin derived peptides in MDCK monolayers: a comparative study with Tat (47-57) and penetratin (43-58). Pharm. Res. 21 (2004) 33-42
24. Cao G., Pei W., Ge H., Liang Q., Luo Y., Sharp F.R., Lu A., Ran R., Graham S.H., and Chen J. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci. 22 (2002) 5423-5431
25. Nagatsu T. The human tyrosine hydroxylase gene. Cell Mol. Neurobiol. 9 (1989) 313-321